Blood Lipids and Its Atherogenic Indices in Alloxan Induced Diabetic Male Rats

O. D. Chikezie¹,²*, S. C. Meludu³,⁴, I. S. I. Ogbu², B. N. Egejuru², T. Ude⁴ and O. Ekuma-Ogbonnia²

¹Department of Chemical Pathology, Federal Medical Centre Umuahia, Abia State, Nigeria.
²Department of Medical Laboratory Science, Chemical Pathology Unit College of Health Sciences and Technology, Nnamdi Azikiwe University, Nnewi Campus, Nigeria.
³Department of Human Biochemistry, Faculty of Basic Medical Sciences, College of Health Sciences, Nnamdi Azikiwe University, Nnewi Campus, Nigeria.
⁴Department of Chemical Pathology, Faculty of Medicine, Nnamdi Azikiwe University, Nnewi Campus, Nigeria.

Authors’ contributions

This work was carried out in collaboration among all authors. Authors ODC and SCM designed the study, performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript. Authors ODC and TU managed the analyses of the study. Authors ISIO, OEO and BNE managed the literature searches. All authors read and approved the final manuscript.

ABSTRACT

Background: Diabetes mellitus is a group of metabolic disorders which result to excessive accumulation of blood sugar over a prolonged period. Due to higher risk of diabetes mellitus to cardiovascular disease, it is crucial to identify and address these cardiovascular risks. This study assessed the effects of diabetes on levels of some blood lipids and its atherogenic indices in diabetic male rats.

Methods: This is an experimental study that involved 40 apparently healthy adult male albino rats (wistar strain) which were randomly assigned to five groups (A, B, C, D and E) of eight (8) animals each. Group A (Normal Control of No intervention for 72 hours), Group B (Diabetic rats of 72 hours post diabetes induction), Group C (metformin treated diabetic rats), Group D (Diabetic Control untreated) and Group E (Normal Control of 3 weeks post diabetes induction). Seven milliliters of...
INTRODUCTION

Diabetes mellitus (DM) also simply known as diabetes, is a group of metabolic disorder which result to excessive accumulation of blood sugar over a prolonged period [1]. Diabetes is a chronic condition that arises when the pancreas produce insufficient insulin, or when the body cannot effectively use the insulin produced. In other words, diabetes has been characterized as a chronic metabolic disorder of multiple etiologies characterized by chronic hyperglycemia with disturbances of carbohydrate, fat, and protein metabolism resulting from defects in insulin secretion, insulin action or both [2,3]. Lipid abnormalities associated with diabetes are termed as dyslipidemia. Dyslipidemia is defined by presence of one or more than one abnormal serum lipid concentration [4]. Diabetes mellitus (DM) is a common comorbidity of hyperlipidemia, particularly, if glycemic control is poor, which in-turn is an important risk factor for atherosclerosis and coronary heart disease. Dyslipidemia is becoming increasingly prevalent all around the world as both insulin deficiency and insulin resistance affects enzymes and pathways of lipid metabolism. Type 2 diabetes is a major risk factor for cardiovascular disease (CVD). The risk of CVD mortality in patients with type 2 diabetes (T2DM) is 2-4 times that observed in individuals without diabetes [5]. It has been observed that about seventy-eight percent of type 2 diabetic patients die from cardiovascular disease, due to premature atherosclerosis which involves dyslipidemia [6]. Many factors contribute to cardiovascular disease risk in diabetes but lipid abnormalities are major contributors. Due to higher risk of diabetes mellitus to cardiovascular disease, it is crucial to identify and address these cardiovascular risks. The measurement of LDL cholesterol alone does not provide sufficient measure of atherogenic risk in hyper-triglyceridemic patients, and a second or several markers are warranted [7].

Early assessment and control of cardiovascular risk factors in patients with T2DM has a positive effect on reducing the risk of CVD and death in patients and improving the prognosis of patients. Work done by VinodMahato et al. [8] and Swaminathan et al. [9] showed a significant increased level of Cardiac risk ratio (CRR) in diabetes mellitus when compared with controls. This shows that cardiac risk ratio could also serves as a good predictor of cardiovascular risk. According to American Heart Association, a value of (>3.5) shows greater propensity towards cardiovascular diseases. Adu et al. [10] also reported a significant increase value of Atherogenic Coefficient (Ac) of diabetes when compared with the non-diabetes subjects which is in agreement with the work of Ikewuchi [11].

Atherogenic Coefficient (AC), calculated as (Non-HDL-c)/HDL-c or (TC-HDL-c)/HDL-c is a measure of cholesterol in LDL, VLDL, IDL fractions with respect to good cholesterol or HDL-c [12]. The atherogenic index of plasma (AIP) is a good predictor of the risk of atherosclerosis and coronary heart disease [13, 14]. The association of TGs and HDL-c in this simple ratio reflects the balance between risk

Keywords: Lipid profile; dyslipidaemia; atherogenic indices; rats.
and protective lipoprotein forces [15]. A study has suggested that the visceral fat area in patients with T2DM is associated with AIP [16].

Non HDL-c is calculated as total cholesterol minus HDL-c. Non-HDL-c has been observed to have the strongest relationship with small dense LDL-c (sdLDL-c) levels when compared with other lipid measurement [17]. The predictive value of non-HDL-C for cardiovascular risk and mortality is better than that of LDL-c [18]. The strong association between non-HDL-c and sdLDL-c adds additional support for using the non-HDL-c level as a predictor of CVD mortality [17].

Therefore, one of the objectives of this study is to assess the cardiovascular risk of diabetes mellitus individuals using Non HDL cholesterol (TC – HDL-c), Cardio Risk Ratio (TC/HDL-c), Atherogenic Index of Plasma (Log TG/HDL-c), Atherogenic Coefficient (TC- HDL-c/ HDL-c) and Atherosclerosis Index (LDL-c/HDL-c).

2. MATERIALS AND METHODS

2.1 Experimental Animals

Forty (40) adult male albino rats (wistar strain) weighing between 100 – 176 g and between 8-10 weeks old, obtained from the animal breeding unit of the Faculty of Veterinary Medicine, University of Nigeria, Nsukka, were used as experimental animals. The rats were kept in cages for two weeks in the Animal House of the College of Health Sciences Nnamdi Azikiwe University Nnewi Campus to acclimatize and had free access to food and water. The animals were maintained under standard laboratory conditions (12 hours light /12 hours dark cycle, temperature of about 37±2°C). All the rats were fed a commercial diet (Vital feed, Nigeria) during the experiment. The protocol was in line with the guidelines of the National Institute of Health (NIH) (NIH Publication 85-23, 1985) for laboratory animal care and use.

2.2 Experimental Design

The Forty (40) adult male wistar rats were randomly assigned to five groups (A, B, C, D and E) of eight (8) animals each. Table 1 summarized the experimental design.

2.3 Induction of Diabetes

In group B, C and D, wistar rats were fasted for 12 – 15 hours, after which diabetes was induced by a single intraperitoneal injection of freshly dissolved Alloxan monohydrate (Sigma-Aldrich, USA) (130 mg/kg b.w) dissolved in 0.5 mL of 10 percent normal saline maintained at 37°C [19, 20]. Normal control rats (Group A and E) received a similar volume of normal saline alone. After 72 hours of alloxan injection, the animals were fasted overnight and their fasting blood glucose was measured. The rats having fasting blood glucose level greater than 200 mg/dL were selected for the study. Fasting blood glucose level of all the diabetes induced rats were greater than 200 mg/dL and were all selected for the study.

2.4 Blood Sample Collection and Serum Preparation

The animals were fasted overnight and sacrificed using chloroform as an anesthetic agent. Blood samples of Groups A and B rats were collected 72 hours post intraperitoneal injection, and that of groups C, D and E rats were collected 3 weeks after confirmation of diabetes. Fasting Blood sample (7 mL) was collected from all the animal through cardiac puncture after 12 hours fasting into a well-labeled, sterile plain bottle. The blood samples were centrifuged at 4000 rpm for 5 minutes after allowing the blood to clot and retract from walls of the sample container at

| Groups | Treatment |
|--------|-----------|
| Group A (Normal Control of 72 hours) | Received 0.5 mL of 10 percent normal saline only + No intervention for 72 hours |
| Group B (Diabetic rats) | Induced diabetes + sacrificed 72 hours of post diabetes induction |
| Group C (Diabetic rats treated) | Induced diabetes + 500 mg/kg, p.o metformin drug treatment for 3 weeks after confirmation of diabetes |
| Group D (Diabetic Control) | Induced diabetes + without metformin drug treatment for 3 weeks after confirmation of diabetes |
| Group E (Normal Control of 3 weeks) | Received 0.5 mL of 10 percent normal saline only + NO intervention for 3 weeks of study |

Table 1. Showing different groups and treatment 72 hours post diabetic induction
room temperature. The sera were separated from the whole blood into a new container and then stored in a refrigerator at −20°C. The analysis was carried out within one week of sample collection. Haemolysed blood samples were not used to avoid error in the result. The blood sample was used for the analysis of total cholesterol (TC), triglycerides (TG) and high density lipoprotein cholesterol (HDL-c) using colorimetric method while low density lipoprotein cholesterol (LDL-c), and very low density lipoprotein cholesterol (VLDL-c), non HDL cholesterol (non HDL-c), cardio risk ratio (CRR), atherogenic index of plasma (AIP), atherogenic coefficient (AC), and atherosclerosis index (AI) were calculated as follows:

\[
\text{In mmol/L LDL} = (\text{Total cholesterol} - (\text{Triglycerides}/2.2) - \text{HDL cholesterol}) \quad [21]
\]

\[
\text{In mmol/dL VLDL} = (\text{Triglycerides}/2.2) \quad [21]
\]

Atherogenic Index of Plasma (AIP) = Log TG/HDL-c. Normal Ranges: ≤ 0.1 [22]

Cardio Risk Ratio (CRR) = TC/HDL-c. Normal Ranges: ≤ 3.5 [23]

Atherogenic Coefficient (AC) = TC/HDL-c. Normal Ranges: ≤ 3.0 [24]

Atherosclerosis Index (AI) = LDL-c/HDL-c. Normal Ranges: ≤ 3.3 [23]

Non HDL cholesterol = TC – HDL-c. Normal Ranges: ≤ 3.3 [25]

Triglycerides were determined by glycerol phosphate oxidase method [26]. Cholesterol was determined using cholesterol oxidase method [27]. High density lipoproteins cholesterol was determined by precipitation with phosphotungstic acid in the presence of magnesium ions [28].

### 3. RESULTS

In Table 2, there was a significant high mean levels of total cholesterol and low density lipoprotein cholesterol in diabetic rats (Group B) and (Groups C and D) when compared with control Groups A and E respectively (P < 0.05). Also, their mean blood levels were significantly higher in Group D when compared with Groups B and C (P < 0.05). Furthermore, there was a significant higher mean level of total cholesterol and low density lipoprotein cholesterol in Group C when compared with the Group B (P < 0.05).

There was no significant difference in the blood mean levels of triglycerides observed when diabetic Group B was compared with control Group A (P > 0.05), but a significant increase was observed when diabetic Groups C and D were compared with control Group E (P < 0.05). Also, a significant increase in mean level of triglyceride was observed in Group D when compared with Group B and C (P < 0.05). No significant difference was seen when diabetic rats Group C is compared with Group B (P > 0.05).

Blood mean level of high density lipoprotein cholesterol was significantly lower in the diabetic rats (Group B) and (Groups C and D) when compared with non diabetic control Groups A and E respectively (P < 0.05). However in Group D, the mean level was also significantly lower when compared with Groups B and C (P < 0.05). No significant difference exists in the mean level of high density lipoprotein cholesterol in Group B when compared with Group C (P > 0.05).

Blood mean level of very low density lipoprotein cholesterol was significantly higher in diabetic rats (Groups B and D) when compared with control Group E (P < 0.05). Very low density lipoprotein cholesterol mean value in Group D was significantly higher when compared with Groups (B and C) (P < 0.05). However, there was no significant difference in the blood mean level in Group B when compared with Groups A and C (P > 0.05).

The blood mean level of non HDL cholesterol was significantly higher in the diabetic rats (Group B) and (Groups C and D) when compared with non diabetic control Groups A and E respectively (P < 0.05). However, the mean level in Group D was significantly higher when compared with Groups B and C respectively, while in Group B, it was significantly
Table 2. Fasting blood lipids and glucose in diabetic and apparently healthy non diabetic male rats (group A-E)

| Parameter                  | Group A n=8 | Group B n=8 | Group C n=8 | Group D n=8 | Group E n=8 | F-value  | P-value |
|----------------------------|-------------|-------------|-------------|-------------|-------------|----------|---------|
| TC (mmol/L)                | 3.26 ±0.17  | 3.69 ±0.26<sup>ac</sup> | 4.39 ±0.29<sup>bde</sup> | 4.96 ±0.37<sup>bce</sup> | 3.35 ±0.12  | 63.254   | < 0.001<sup>*</sup> |
| TG                         | 1.54 ±0.07  | 1.76 ±0.19<sup>d</sup> | 1.85 ±0.22<sup>de</sup> | 2.72 ±0.34<sup>bce</sup> | 1.55 ±0.04  | 49.947   | < 0.001<sup>*</sup> |
| HDLc                       | 1.52 ±0.07  | 1.30 ±0.13<sup>d</sup> | 1.32 ±0.06<sup>de</sup> | 0.98 ±0.05<sup>bce</sup> | 1.54 ±0.06  | 58.103   | < 0.001<sup>*</sup> |
| LDLc                       | 1.04 ±0.21  | 1.59 ±0.28<sup>ad</sup> | 2.24 ±0.31<sup>bde</sup> | 2.74 ±0.44<sup>bce</sup> | 1.10 ±0.15  | 51.736   | < 0.001<sup>*</sup> |
| VLDLc                      | 0.70 ±0.03  | 0.79 ±0.09<sup>d</sup> | 0.84 ±0.10<sup>de</sup> | 1.24 ±0.14<sup>bce</sup> | 0.70 ±0.02  | 50.308   | < 0.001<sup>*</sup> |
| FBS                        | 4.83 ±0.32  | 17.58 ±4.36<sup>ac</sup> | 9.27 ±1.77<sup>bde</sup> | 19.09 ±2.83<sup>bde</sup> | 4.86 ±0.33  | 61.847   | < 0.001<sup>*</sup> |

Key: <sup>*</sup>- Significant when compared with Group A (Normal Control of 72 hours), <sup>**</sup>- Significant when compared with Group B (Diabetic Rats), <sup>***</sup>- Significant when compared with Group C (Diabetic Rats), <sup>****</sup>- Significant when compared with Group D (Diabetic Control), <sup>*****</sup>- Significant when compared with Group E (Normal Control of 3 weeks), Group A (Normal Control of 72 hours) - Received 0.5mL of 10 percent normal saline only, Group B (Diabetic Rats) - Induced diabetes + sacrificed 72 hours of post diabetes induction, Group C (Diabetic Rats) - Induced diabetes + 500 mg/kg, p.o metformin drug treatment for 3 weeks after confirmation of diabetes, Group D (Diabetic Control) - Induced diabetes + without metformin drug treatment for 3 weeks after confirmation of diabetes, Group E (Normal Control of 3 weeks) - Received 0.5mL of 10 percent normal saline only, TC- Total Cholesterol, TG- Triglycerides, HDLc- High Density Lipoprotein Cholesterol, LDLc- Low Density Lipoprotein Cholesterol, VLDLc- Very Low Density Lipoprotein Cholesterol and FBS- Fasting Blood Sugar.

Table 3. Lipids atherogenic indices in diabetic and apparently healthy non diabetic male rats (group A-E)

| Parameter                  | Group A n=8 | Group B n=8 | Group C n=8 | Group D n=8 | Group E n=8 | F-value  | P-value |
|----------------------------|-------------|-------------|-------------|-------------|-------------|----------|---------|
| Non-HDL                    | 1.74 ±0.19  | 2.39 ±0.21<sup>bcd</sup> | 3.08 ±0.29<sup>bde</sup> | 3.98 ±0.43<sup>bce</sup> | 1.81 ±0.14  | 96.648   | < 0.001<sup>*</sup> |
| CRR                        | 2.15 ±0.16  | 2.84 ±0.23<sup>ad</sup> | 3.33 ±0.25<sup>bde</sup> | 5.09 ±0.68<sup>bce</sup> | 2.18 ±0.12  | 94.539   | < 0.001<sup>*</sup> |
| AIP                        | 0.01 ±0.00  | 0.13 ±0.06<sup>ad</sup> | 0.14 ±0.05<sup>bde</sup> | 0.44 ±0.07<sup>bce</sup> | 0.01 ±0.00  | 116.229  | < 0.001<sup>*</sup> |
| AC                         | 1.15 ±0.16  | 1.84 ±0.23<sup>ad</sup> | 2.33 ±0.25<sup>bde</sup> | 4.09 ±0.68<sup>bce</sup> | 1.18 ±0.12  | 94.480   | < 0.001<sup>*</sup> |
| AI                         | 0.69 ±0.16  | 1.22 ±0.23<sup>ad</sup> | 1.69 ±0.26<sup>bde</sup> | 2.81 ±0.58<sup>bce</sup> | 0.71 ±0.10  | 63.294   | < 0.001<sup>*</sup> |

Key: <sup>*</sup>- Significant when compared with Group A (Normal Control of 72 hours), <sup>**</sup>- Significant when compared with Group B (Diabetic Rats), <sup>***</sup>- Significant when compared with Group C (Diabetic Rats), <sup>****</sup>- Significant when compared with Group D (Diabetic Control), <sup>*****</sup>- Significant when compared with Group E (Normal Control of 3 weeks), Group A (Normal Control of 72 hours) - Received 0.5mL of 10 percent normal saline only, Group B (Diabetic Rats) - Induced diabetes + sacrificed 72 hours of post diabetes induction, Group C (Diabetic Rats) - Induced diabetes + 500 mg/kg, p.o metformin drug treatment for 3 weeks after confirmation of diabetes, Group D (Diabetic Control) - Induced diabetes + without metformin drug treatment for 3 weeks after confirmation of diabetes, Group E (Normal Control of 3 weeks) - Received 0.5mL of 10 percent normal saline only, Non HDL- Non HDL cholesterol, CRR- Cardio Risk Ratio, AIP- Atherogenic Index of Plasma, AC- Atherogenic Coefficient and AI- Atherosclerosis Index.
lower when compared with Group C (P < 0.05). Blood mean levels of cardio risk ratio, atherogenic index of plasma, atherogenic coefficient, and atherosclerosis index were all significantly higher in diabetic rats (Group B) and (Groups C and D) when compared with Control Groups A and E respectively (P < 0.05). Furthermore in Group D, mean levels of cardio risk ratio, atherogenic index of plasma, atherogenic coefficient and atherosclerosis index were also significantly higher when compared with Groups B and C (P < 0.05). There was no significant difference in their mean levels when Group B is compared with Group C (P > 0.05) as showed in Table 3.

4. DISCUSSION

Diabetes is commonly associated with abnormalities in plasma lipids and lipoproteins levels. In particular, it usually presents with concomitant elevations in plasma lipids. Abnormalities in the lipid profile are one of the most common complications in diabetes and are associated with an increased risk of coronary heart disease; therefore, an ideal treatment for diabetes should have a favorable effect on the lipid profile in addition to offering good glycemic control [30].

The high concentration of triglycerides, total cholesterol, low density lipoprotein cholesterol, very low density lipoprotein cholesterol and lower concentration of high density lipoprotein cholesterol observed in diabetic rats compared to normal rats group, agreed with report of Pierre et al. [31]. Also, significantly lower serum concentration of triglycerides, total cholesterol, low density lipoprotein cholesterol, very low density lipoprotein concentration and higher level of high density lipoprotein cholesterol observed in diabetic treated rats compared to untreated diabetic rats group was in agreement with the work of Vishnu et al. [32]. This finding suggests that an elevated glucose level will occur upon induction of diabetes, and this would give rise to corresponding increase in plasma lipids concentration. Hyperlipidaemia is a factor of cardiovascular diseases associated with diabetes mellitus. It is often characterized by elevated cholesterol, triglycerides, phospholipids and other lipoproteins [33]. Several mechanisms may account for the atherogenic lipid abnormalities in diabetic patients. Dysfunctional adipose tissue is less sensitive to insulin and has reduced hormone-sensitive lipase activity compared with normal adipose tissue. As a result, there is an increased breakdown of intracellular triglycerides and increased release of free fatty acids into the circulation, leading to fatty infiltration in the liver, muscles and pancreatic β-cells leading to predisposition to type 2 diabetes. Increased hepatic free fatty acids contribute to increased hepatic triglycerides synthesis in turn resulting in elevated concentrations of very low density lipoproteins particles. Various lipases contribute to remodeling of very low density lipoproteins to small, dense low density lipoproteins particles. In addition, cholesterol ester transfer protein exchanges triglycerides from very low density lipoproteins to cholesterol found in high density lipoproteins and low density lipoproteins, leading to cholesterol-rich atherogenic very low density lipoproteins particles. High density lipoproteins particles that undergo these modifications are cleared more readily by the kidney, resulting in lower high density lipoproteins cholesterol levels [34].

Several epidemiological studies have found that in type 2 diabetic patients, metformin improves vascular function and reduces cardiovascular events and mortality by mechanisms that are not entirely attributed to its anti-hyperglycemic effects [35]. This study finds significant higher plasma level of non HDL cholesterol, cardio risk ratio, atherogenic index of plasma, atherogenic coefficient, and atherosclerosis index in diabetic animals compared to control group. Also, a significant lower level was observed in non HDL cholesterol, cardio risk ratio, atherogenic index of plasma, atherogenic coefficient and atherosclerosis index in metformin treated diabetic animal compared with untreated animal. Findings of this study is in agreement with the work of Rajesh et al. [36] which finds atherogenic index of plasma higher in diabetic animals compared to normal control, which upon treatment with metformin lowers the atherogenic index. The results showed that metformin have a beneficial effect in type 2 diabetes, including improved lipid profiles, and enhanced endothelial function. This would eventually improve atherogenic risk in diabetic subjects. Several studies have suggested that metformin may improve some of the features of the metabolic syndrome as it not only improves insulin sensitivity in the liver and muscle, as its primary anti-hyperglycemic mechanism of action, but also induces additional beneficial effects on several metabolic abnormalities associated with the metabolic syndrome [37,38,39]. A study also reported that metformin induced improvement of metabolic disorders that is associated with the energy state of the body, reduction of
macrovascular morbidity and mortality, anti-atherogenic, anti-inflammatory and antioxidant effects [40].

5. CONCLUSION

In conclusion, atherogenic indices can serve as predictive pointer for future cardiovascular event especially, when LDLc value is normal. Also hyperglycemia could cause significant alterations of lipids, but metformin treatment has showed not only hypoglycemic effect, but also anti-hyperlipidemic properties.

ETHICAL APPROVAL

Ethical approval was sought and obtained from the Research Ethics Committee of the Federal Medical Centre (FMC) Umuahia with reference FMC/GEH/G.596/VOL.10/282. The protocol was in line with the guidelines of the National Institute of Health (NIH) (NIH Publication 85-23, 1985) for laboratory animal care and use.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. American Diabetes Association. Diagnosis and classification of diabetes. Diabetes Care. 2004;27(1):5–14.
2. Alebiosu CO. Clinical diabetic nephropathy in a tropical African population. West African Journal of Medicine. 2003;22(2): 152-155.
3. Kasiam LO, Long-Mbenga B, Nge OA, Kangola KN, Mbungu FS, Milongo DG. Classification and dramatic epidemic of diabetes mellitus in Kinshasa hinterland: The prominent role of type 2 diabetes and lifestyles changes among Africans. Nigerian Journal of Medicine. 2009;18(3): 311-320.
4. Menik HL, Sammanthi JS, Priyanthaa WT, Wijewickrama GS, Shalika P, Kotapola I. Significant genetic association between insulin resistance and total cholesterol in type 2 diabetes mellitus- A Preliminary Observation. Online Journal of Health and Allied Sciences. 2005;4(1).
5. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Kondapally Seshasai SR, Gobin R, Kaptoge K, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. The Lancet. 2010;375(9733):2215–2222.
6. Eschwe’ge E. The dysmetabolic syndrome, insulin resistance and increase in cardiovascular mortality and morbidity in type 2 diabetes: etiological factors in the development of cardiovascular complications. Diabetes Metabolism. 2003; 29(4-2):6519-6527.
7. National Cholesterol Education Program (NCEP) Expert Panel. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-3421.
8. VinodMahato R, Gyawali P, Raut PP, Regmi P, Singh KP, Pandeya DR, Gyawali P. Association between glycaemic control and serum lipid profile in type 2 diabetic patients: Glycatedhaemoglobin as a dual biomarker. Biomedical Research. 2011;22 (3):375-380.
9. Swaminathan S, Priya G, Revathy K. Emila S. Non HDL-C as an alternate to LDL-C for the diagnosis of cardiovascular disease. Journal Pharmaceutical and Biomedical Sciences. 2013;30(30):913-919.
10. Adu EM, Ukwamedu HA, Oghagbon ES. Assessment of cardiovascular risk indices in type 2 diabetes mellitus. Tropical Medicine and Surgery. 2015;3(2):184. DOI: 10.4172/2329-9088.1000184
11. Ikewuchi CC. Effect of Aqueous Extract of Sansevieria senegambica baker on plasma chemistry, lipid profile and atherogenic indices of alloxan treated rats: implications for the management of cardiovascular complications in diabetes mellitus. Pacific Journal of Science and Technology. 2010; 11:524-531.
12. Bhawardj S, Bhattacharjee J, Bhatnagar MK, Tyagi S. Atherogenic index of plasma, Castelli risk index and atherogenic coefficient- new parameters in assessing cardiovascular risk. International Journal of Pharma and Bio Sciences. 2013;3(3):359-364.
13. Nwagha UI, Ikekepeazu EJ, Ejezie FE, Neboh EE, Maduka IC. Atherogenic index of plasma as useful predictor of cardiovascularrisk among postmenopausal
women in Enugu, Nigeria. African Health Sciences. 2010;10(3):248–252.
14. Cai G, Shi G, Xue S, Lu W. The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population. Medicine. 2017;96(37):8058.
15. Dobiásová M, Frohlich J, Sedová M, Cheung MC, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. Journal of Lipid Research. 2011;52(3):566-571.
16. Song P, Xu L, Xu J, Zhang HQ, Yu CX, Guan QB, Zhao M, Zhan X. Atherogenic index of plasma is associated with body fat level in type 2 diabetes mellitus patients. Current Vascular Pharmacology. 2018;16(6):589–595.
17. Srissawasdi P, Chaloeysup S, Teerajetgul Y, Pocathikorn A, Sukasem C, Vanavanavan S, Kroll, MH. Estimation of plasma small dense LDL cholesterol from classic lipid measures. American Journal of Clinical Pathology. 2011;136(1):20-29.
18. Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. American Journal of Cardiology. 2008;101(7):1003-1008.
19. Dallatu MK, Anaja PO, Bilbis LS, Mojiminiyi FBO, Mohammed A, Tanko Y. Hematological and antioxidant properties of alloxan-induced diabetes rats supplemented with antioxidant micronutrients. Nigerian Journal of Basic and Applied Science. 2010;18(1):106-111.
20. Mule VS, Naikwade NS, Magdum CS, Jagtap VA. Antidiabetic activity of extracts of *Pitheccllum dulce* Benth leaves in alloxan induced diabetic rats. International Journal of Pharmaceutical Sciences and Drug Research. 2016;8(5):275-280.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry. 1990;36(7):15-19.
22. Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apoB lipoprotein depleted plasma (FER (HDL)). Clinical Biochemistry. 2001;34(7):583-588.
23. Brehm A, Pfeiler G, Pacini G, Vierhapper H, Roden M. Relationship between serum lipoprotein ratios and insulin resistance in obesity. Clinical Science. 2004;50(12):2316-2322.
24. Harini DN, Ambika DK, Prabath KD, Vani N. Lipid ratios, atherogenic coefficient and atherogenic index of plasma as parameters in assessing cardiovascular risk in type 2 diabetes mellitus. International Journal of Research in Medical Sciences. 2016;4(7):2863-2869.
25. Suchitra MM, Sheshu KM, Bitta AR, Rao AM, Alok S. Atherogenic dyslipidemia in diabetic nephropathy: lipoprotein: A lipid ratios and atherogenic index. International Journal of Research in Medical Sciences. 2013;1(4):455-459.
26. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clinical Chemistry. 1982;28(10):2077-2080.
27. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clinical Chemistry. 1974;20(4):470-475.
28. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. Scandinavian Journal of Clinical and Laboratory Investigation. 1980:40:583-595.
29. Levesque R. A guide for SPPSS and SAS users, SPSS programming and data management, (4th edition), 233 south wacker drive, 11th floor, Chicago, United State of America. 2007:2-540.
30. Azizi R, Salemi Z, Goodarzi MT. Effect of Biochanin - A on serum visfatin levels in STZ-induced diabetic rats. Iran Red Crescent Medical Journal. 2014;16(9):1–7.
31. Pierre W, Gildas AJ, Ulrich MC, Modeste WN, Benoit NT, Albert K. Hypoglycemic and hypolipidemic effects of Bersama engleriana leaves in nicotinamide/streptozotocin-induced type 2 diabetic rats. BMC Complementary and Alternative Medicine. 2012;12:264. Available:https://www.ncbi.nlm.nih.gov/pubmed/23267560.
32. Brehm A, Pfeiler G, Pacini G, Vierhapper H, Roden M. Relationship between serum lipoprotein ratios and insulin resistance in obesity. Clinical Science. 2004;50(12):2316-2322.
33. Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, Clark NG. Weight management through lifestyle modification for the prevention of type 2 diabetes: Rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity and the American Society for Clinical Nutrition. American Journal of Clinical Nutrition. 2004;80(2):257-263.

34. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27(6):1496-1504.

35. Manjusha KB, Ipseeta RM, Ujwala M, Rajesh KS, Deshmukh YA. Myocardial salvaging effects and mechanisms of metformin in experimental diabetes. International Journal of Basic and Clinical Pharmacology. 2016;5(2):341-349.

36. Rajesh KS, Ipseeta RM, Ujwala M, Manjusha KB, Deshmukh, YA. Metformin ameliorates diabetes with metabolic syndrome induced changes in experimental rats. International Journal of Biomedical Research. 2016;7(2):55-65.

37. Hundal RS, Inzucchi SE. Metformin new understandings, new uses. Drugs. 2003;63(18):1879–1894.

38. Viollet B, Guigas B, Leclerc J, Hebrard S, Lantier L, Mounier R, Andreelli F, Foretz M. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiologica. 2009;196(1):81–90.

39. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nature Revives, Molecular Cellular Biology. 2012;13(4):251–262.

40. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. Journal of Clinical Investigation. 2010;120(7):2355–2369.